A Phase I Open-Label Study With 200 mg Intravenous TR-701 Free Acid to Assess Safety and Pharmacokinetics in Advanced Renal Impairment Subjects.
Phase of Trial: Phase I
Latest Information Update: 04 May 2016
At a glance
- Drugs Tedizolid (Primary)
- Indications Bacterial infections
- Focus Pharmacokinetics
- Sponsors Trius Therapeutics
- 08 Jun 2012 Actual end date changed from May 2012 to Mar 2012 as reported by ClinicalTrials.gov.
- 07 Jun 2012 Actual end date (May 2012) added as reported by ClinicalTrials.gov.
- 07 Jun 2012 Status changed from recruiting to completed as reported by ClinicalTrials.gov.